TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $16,618,037 | +7.8% | 2,021,659 | +1.1% | 1.28% | -20.6% |
| Q1 2024 | $15,420,000 | -14.2% | 2,000,000 | 0.0% | 1.61% | -19.0% |
| Q4 2023 | $17,980,000 | +106.8% | 2,000,000 | +105.6% | 1.99% | +40.1% |
| Q3 2023 | $8,695,062 | -61.1% | 972,602 | -33.1% | 1.42% | -53.7% |
| Q2 2023 | $22,344,653 | -36.5% | 1,454,730 | -7.0% | 3.07% | -32.3% |
| Q1 2023 | $35,165,252 | +299.9% | 1,563,595 | +274.0% | 4.54% | +236.5% |
| Q4 2022 | $8,792,622 | -14.4% | 418,099 | +0.3% | 1.35% | -37.7% |
| Q3 2022 | $10,268,000 | -65.7% | 416,729 | -66.3% | 2.16% | -71.7% |
| Q2 2022 | $29,928,000 | +33.3% | 1,235,151 | +41.8% | 7.64% | +5.0% |
| Q1 2022 | $22,444,000 | +297.1% | 870,918 | +378.3% | 7.28% | +141.0% |
| Q4 2021 | $5,652,000 | – | 182,103 | – | 3.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |